Nexalin Technology, Inc. (NXL)
| Market Cap | 8.80M -51.9% |
| Revenue (ttm) | 275,582 +110.3% |
| Net Income | -8.33M |
| EPS | -0.46 |
| Shares Out | 21.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 317,466 |
| Open | 0.3600 |
| Previous Close | 0.3629 |
| Day's Range | 0.3600 - 0.4291 |
| 52-Week Range | 0.3050 - 2.0000 |
| Beta | 4.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid... [Read more]
Financial Performance
In 2025, Nexalin Technology's revenue was $301,647, an increase of 78.78% compared to the previous year's $168,721. Losses were -$8.22 million, 8.08% more than in 2024.
Financial StatementsNews
Nexalin Technology Proxy statement: Proxy filing
Nexalin Technology filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Nexalin Technology investigator wins award for neurostimulation research
Nexalin Technology (NXL) announced that Victor Fontenelle Bastos de Lima, an investigator on the company’s completed Brazilian clinical study, received the Young Researcher Award at the BRAIN 2026 con...
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emot...
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life
Nexalin Technology completes neurostimulation protocol trial
Nexalin Technology (NXL) announced the completion of an 8-week, single-center, prospective, open-label clinical trial evaluating Nexalin’s proprietary 15 milliamp, 77.5 Hz neurostimulation protocol in...
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up
Nexalin Technology Registration statement
Nexalin Technology filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
Nexalin Technology Quarterly report
Nexalin Technology has published a quarterly earnings report on June 8, 2026.
Nexalin Technology announces issuance of new U.S. patent
Nexalin Technology (NXL) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: “Transcranial Alternating Current Dynamic Frequency Stimulation Met...
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurost...
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant tra...
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-int...
Nexalin Technology Quarterly report: Q1 2026
Nexalin Technology has published its Q1 2026 quarterly earnings report on May 8, 2026.
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
Nexalin Technology enters agreements to advance HALO Clarity trial
Nexalin Technology (NXL) entered into agreements to advance its planned pivotal clinical trial evaluating the HALO Clarity device for the treatment of moderate-to-severe insomnia, with patient enrollm...
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designe...
Nexalin Technology advances FDA Alzheimer’s strategy
Nexalin Technology (NXL) announced the completion of a series of high-level meetings in the United States and China focused on advancing the Company’s global clinical strategy for the treatment of…
Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the b...
Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin's differentiated, non-i...
Nexalin Technology price target lowered to $2 from $4 at Maxim
Maxim lowered the firm’s price target on Nexalin Technology (NXL) to $2 from $4 and keeps a Buy rating on the shares. The firm is citing its lower revenue estimates…
Nexalin Technology Annual report: Q4 2025
Nexalin Technology has published its Q4 2025 annual report on March 25, 2026.
Nexalin Technology Slides: Investor presentation
Nexalin Technology has posted slides in relation to its latest quarterly earnings report, which was published on March 1, 2026.
Nexalin announces continued advancement toward trial evaluating HALO Clarity
Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin...
Nexalin announces continued advancement toward trial evaluating HALO Clarity
Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin...